Skip to main navigation menu Skip to main content Skip to site footer

User Navigation

Peer-reviewed scientific and practical journal · since 2006

ISSN 2306-4137
Современная терапия психических расстройств
Current Therapy of Mental Disorders

NEW MEDICINES

RECOVERY FROM SCHIZOPHRENIA: ROLE OF MODERN INJECTABLE ANTIPSYCHOTICS-PROLONGS

Author information
N.N. Petrova
Saint-Petersburg State University, department of psychiatry and narcology
Published
June 30, 2022
Pages
44-52
PDF (Русский)

Abstract

Currently, the goal of schizophrenia therapy is considered to be recovery, but the concept of "recovery" is not fully formed, the question of the relationship between recovery and remission is open, its criteria and factors influencing the achievement of recovery are clarified. The aim of the literature review was to analyze the problem of recovery in schizophrenia. The goal of the study was to discuss basic concept of recovery and the role of injectable second-generation prolonged-acting antipsychotics in achieving recovery in patients with schizophrenia.

Methods. A literature review was conducted in PubMed and Google using various combinations of keywords: schizophrenia, remission, recovery, injectable antipsychotics of the second generation of prolonged action. Literature lists of all identified publications were manually checked for additional articles and for relevance to the problem at hand. Inclusion criteria: relevant full-text articles, systematic reviews, and meta-analyses of schizophrenia recovery. Exclusion criteria: clinical trial publications, low-quality articles.

Results. Current views on the concept of recovery, the relationship between recovery and symptomatic and functional remission, the components of recovery and criteria of its evaluation, factors important for achieving recovery are presented. The value of prolonged antipsychotic therapy in the form of injections has been shown not only to control the symptomatology of schizophrenia, but also to improve functioning and quality of life of patients.

Conclusion. Functional outcome should be a priority goal for therapeutic interventions in schizophrenia. Only a comprehensive and multifaceted approach that includes effective pharmacotherapy can improve outcome in schizophrenia. The use of second-generation injectable antipsychotic prolongers contributes to the chances of recovery in patients with schizophrenia

Keywords

  • schizophrenia
  • remission
  • recovery
  • injectable antipsychotics of the second generation of prolonged action

How to Cite

Petrova, N. (2022). RECOVERY FROM SCHIZOPHRENIA: ROLE OF MODERN INJECTABLE ANTIPSYCHOTICS-PROLONGS. Current Therapy of Mental Disorders, (2), 44–52. https://doi.org/10.21265/PSYPH.2022.54.10.005
Endnote/Zotero/Mendeley (RIS) BibTeX

References

  1. Moller H.J., Bottlender R., Wegner U. et al. Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome//Acta Psychiatrica Scandinavica.- 2000.- Vol. 102.- P. 54–57. doi: 10.1034/j.1600-0447.2000.00010.x. PMID: 11261641.
  2. Шизофрения Клинические рекомендации. Взрослые. Электронное издание. Минздрав РФ. Москва, 2021. - 134 с. https://cr.minzdrav.gov.ru/recomend/451_2
  3. Andreasen N.C., Carpenter W.T. Jr, Kane J.M. et al. Remission in schizophrenia: proposed criteria and rationale for consensus// Am J Psychiatry. – 2005. – Vol.162, №3.- P.441-9. doi: 10.1176/appi.ajp.162.3.441. PMID: 15741458.
  4. Emsley R, Chiliza В, Asmal L, Lehloenya К. The concepts of remission and recovery in schizophrenia// Current Opinion in Psychiatry.- 2011.-Vol.24.- P. 114–121. DOI:10.1097/YCO.0b013e3283436ea3
  5. Mosolov S., Potapov A.V., Ushakov U.V. et al. Design and validation of standardized clinical and functional remission criteria in schizophrenia // Neuropsychiatric Disease and Treatment. – 2014.- Vol.10.- P.167-181. DOI:10.2147/NDT.S46799
  6. Мосолов С.Н., Потапов А.В., Шафаренко А.А. с соавт. Валидизация стандартизированных клинико-функциональных критериев ремиссии при шизофрении // Социальная и клиническая психиатрия. – 2011. – Т. 21, № 3. – С. 63–42.
  7. Мосолов С.Н., Потапов А.В., Цукарзи Э.Э. Стандартизированные клинико-функциональные критерии терапевтической ремиссии при шизофрении. Методические указания. М., ФГБУ «НМИЦПН им. В.П. Сербского» МЗ РФ. – 2017. – 73 с.
  8. Coryell W. Schizoaffective and schizophreniform disorders. The medical basis of psychiatry. Springer, New York, NY, 2016.- P. 121–135.
  9. Juckel G., de Bartolomeis A., Gorwood Ph. et al. Towards a framework for treatment effectiveness in schizophrenia // Neuropsychiatric Disease and Treatment. – 2014. - №10. - P.1867-1878. DOI 10.17116/jnevro202012006282
  10. Silva M.A., Restrepo D. Functional Recovery in Schizophrenia // Rev Colomb Psiquiatr (Engl Ed). - 2019. - Vol. 48, №4. - P. 252-260. English, Spanish. doi: 10.1016/j.rcp.2017.08.004.
  11. Harvey P.D., Bellack A.S. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?// Schizophr. Bull. -2009.- Vol. 35.- P. 300–306. doi: 10.1093/schbul/sbn171. Epub 2009 Jan 6.
  12. Shrivastava A, Johnston M, Shah N, Bureau Y. Redefining outcome measures in schizophrenia: integrating social and clinical parameters//Curr Opin Psychiatry.- 2010.- Vol. 23, №2.-P.120–126. doi: 10.1097/YCO.0b013e328336662e.
  13. Liberman R.P. Recovery frоm schizophrenia: form follows functioning // World Psychiatry. -2012.- Vol. 11, №3.- P. 161–162. doi:10.1002/j.2051-5545.2012.tb00118.x
  14. Liberman R.P., Kopelowicz A., Ventura J. et al. Operational criteria and factors related to recovery from schizophrenia//International Review of Psychiatry.-2002.-№14. – P. 256–272. https://doi.org/10.1080/0954026021000016905
  15. Torgalsbøen A. What is recovery in schizophrenia? In: Severe Mental Illness, Research Evidence and Implications for Practice. Edited by Provencher HL, Keyes CLM (editors). Boston, MA: Boston University; 2013.-P. 302–315.
  16. Nasrallah H.A., Targum S.D., Tandon R. et al. Defining and measuring clinical effectiveness in the treatment of schizophrenia //Psychiatr. Serv. – 2005. – Vol. 56, №3. – P. 273–282. doi: 10.1176/appi.ps.56.3.273.
  17. Bandura A. Self-efficacy beliefs of adolescents. New York: Information Age Publishing, 2006.-380 p.
  18. Bellack A.S., Drapalski A. Issues and developments on the consumer recovery construct//World Psychiatry.- 2012.- Vol.11, №3.- P.156-60. doi: 10.1002/j.2051-5545.2012.tb00117.x. PMID: 23024667; PMCID: PMC3449339.
  19. Resnick S.G., Rosenheck R.A., Lehman A.F. An exploratory analysis of correlates of recovery//Psychiatr Serv.- 2004.- Vol. 55.- P.540–547. doi: 10.1176/appi.ps.55.5.540.
  20. Roe D., Mashiach-Eizenberg M., Lysaker P.H. The relation between objective and subjective domains of recovery among persons with schizophrenia related disorders//Schizophr Res.- 2011.- Vol. 131.- P. 133–138. doi: 10.1016/j.schres.2011.05.023.
  21. Jørgensen R., Zoffmann V., Munk-Jørgensen P. et al. Relationships over time of subjective and objective elements of recovery in persons with schizophrenia// Psychiatry Res.- 2015.- Vol. 228.- P.14–19. doi: 10.1016/j.psychres.2015.03.013.
  22. Гурович И.Я., Любов Е.Б., Сторожакова Я.А. Выздоровление при шизофрении. Концепция «Recovery»// Социальная и клиническая психиатрия. - 2008.- Т.18, №2.-С.7-14.
  23. И. Я. Гурович, Н. Г. Шашкова, Л. Я. Висневская, Я. А. Сторожакова RECOVERY (ЛИЧНОСТНО-СОЦИАЛЬНОЕ ВОССТАНОВЛЕНИЕ) ПРИ ШИЗОФРЕНИИ: ОБСУЖДЕНИЕ ПРОБЛЕМЫ И ПЕРСПЕКТИВ МОДЕЛИ ПОТРЕБИТЕЛЕЙ ПСИХИАТРИЧЕСКОЙ ПОМОЩИ// СОЦИАЛЬНАЯ И КЛИНИЧЕСКАЯ ПСИХИАТРИЯ.- 2013.- Т. 23, № 2. - С. 89-95.
  24. Andresen R., Oades L., Caputi P. The experience of recovery from schizophrenia: towards an empirically validated stage model// Aust N Z J Psychiatry.- 2003.- Vol. 37.- P. 586–594. doi: 10.1046/j.1440-1614.2003.01234.x. PMID: 14511087.
  25. Slade M., Amering M., Farkas M. et al. Uses and abuses of recovery: implementing recovery-oriented practices in mental health systems// World Psychiatry.- 2014.- Vol.13.-P.12–20. doi: 10.1002/wps.20084.
  26. Lysaker P.H., Roe D., Buck K.D. Recovery and wellness amidst schizophrenia: definitions, evidence, and the implications for clinical practice// J Am Psychiatr Nurses Assoc.- 2010.- Vol. 16.- P. 36–42. doi: 10.1177/1078390309353943.
  27. Galderisi S., Rossi A., Rocca P. et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia// World Psychiatry.- 2014.- Vol. 13.-P. 275–287. doi: 10.1002/wps.20167.
  28. Mucci A., Galderisi S., Gibertoni D. et al. Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses// JAMA Psychiatry.- 2021.- Vol.78, №5.- P. 550-559. doi: 10.1001/jamapsychiatry.2020.4614.
  29. Harvey P.D., Strassnig M. Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status// World Psychiatry.- 2012.- Vol. 11.- P. 73–79. doi: 10.1016/j.wpsyc.2012.05.004
  30. Park S.G., Bennett M.E., Couture S.M., Blanchard J.J. Internalized stigma in schizophrenia: relations with dysfunctional attitudes, symptoms, and quality of life// Psychiatry Res.- 2013.- Vol.205.-P.43–47. doi: 10.1016/j.psychres.2012.08.040. Epub 2012 Sep 17.
  31. Jääskeläinen E., Juola P., Hirvonen N. et al. A systematic review and metaanalysis of recovery in schizophrenia//Schizophr Bull.- 2013.- Vol. 39.- P. 1296–1306. doi: 10.1093/schbul/sbs130.
  32. Deutschenbaur L., Lambert M., Walter M. et al. Pharmakologische Langzeitbehandlung schizophrener Erkrankungen [Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy]// Nervenarzt.- 2014.- Vol. 85, №3.- P. 363-75; quiz 376-7. German. doi: 10.1007/s00115-013-3807-7. PMID: 24603949.
  33. Alvarez-Jimenez M., Gleeson J.F., Hen¬ry L.P. et al. Road to full reco¬very: longitudinal relationship bet¬ween symptomatic remission and psychosocial recovery in first-episo¬de psychosis over 7.5 years// Psychol Med.- 2012.- Vol. 42.- P. 595–606. doi: 10.1017/S0033291711001504. Epub 2011 Aug 19. PMID: 21854682.
  34. Vita A., Barlati S. Recovery from schizophrenia: is it possible? //Curr Opin Psychiatry. -2018.- Vol.31, №3.- P. 246-255. doi: 10.1097/YCO.0000000000000407. PMID: 29474266.
  35. Петрова Н.Н., Григорьева Е.В. Инъекционные антипсихотики-пролонги второй генерации в клинической практике//Журнал неврологии и психиатрии им. С.С. Корсакова. – 2022.- Т.122, №2.- С. 132–140. https://doi.org/10.17116/jnevro2022122021132
  36. Correll C.U., Citrome L., Haddad P.M. et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence// J Clin Psychiatry.-2016.-Vol. 77(suppl 3).- P. 1-24. doi: 10.4088/JCP.15032su1.
  37. Kane J.M., Correll C.U. Optimizing treatment choices to improve adherence and outcomes in schizophrenia// J. Clin. Psychiatry.- 2019.- Vol. 80, №5.- IN18031AH1C. doi: 10.4088/JCP.IN18031AH1C. PMID: 31536686.
  38. Savitz A.J., Xu H., Gopal S. et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study// Int. J. Neuropsychopharmacol.- 2016.- Vol. 19, №7.-pyw018. doi: 10.1093/ijnp/pyw018.
  39. Kane J.M., Schooler N.R., Marcy P. et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial [published correction appears in JAMA Psychiatry. 2020;77(12):1310]//JAMA Psychiat.- 2020.- Vol. 77, №12.- P. 1217–24. https:// doi. org/ 10. 1001/ jamap sychi atry.2020. 2076.
  40. Subotnik K.L., Casaus L.R., Ventura J. et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial// JAMA Psychiatry.- 2015. – Vol. 72, №8.- P. 822–829. doi: 10.1001/jamapsychiatry.2015.0270.
  41. Tiihonen J., Haukka J., Taylor M. et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophre¬nia// Am J Psychiatry.- 2011.- Vol. 168.-P. 603–609. doi: 10.1176/appi.ajp.2011.10081224.
  42. Bartzokis G., Lu P.H., Raven E.P. et al. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia// Schizophr. Res. - 2012.- Vol.140, №1–3.- P. 122–128. doi: 10.1016/j.schres.2012.06.036.
  43. Phahladira L., Luckhoff H.K., Asmal L. et al. Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders//npj Schizophr.- 2020.-Vol. 6, №2. https://doi.org/10.1038/s41537-019-0091-y
  44. Schreiner A., Aadamsoo K., Altamura A.C. et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia// Schizophr. Res.- 2015.- Vol. 169, №1–3.- P. 393–399. doi: 10.1016/j.schres.2015.08.015. Epub 2015 Oct 1. PMID: 26431793.
  45. Alphs L., Brown B., Turkoz I. Nuechterlein KH. et al. The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder// Schizophr Res. – 2022.- Vol. 243.- P. 86-97. doi: 10.1016/j.schres.2022.02.019. Epub ahead of print. PMID: 35247794.
  46. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. // World J Biol Psychiatry 2013, 14 (1):2-44.
  47. Sajatovic M., Ross R., Legacy S.N. et al. Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder—expert consensus survey part 2// Neuropsychiatr Dis Treat.- 2018.- Vol.14.- P. 1475–92. https:// doi. org/ 10. 2147/ NDT. S1674 85.
  48. Lieberman J.A., Girgis R.R., Brucato G. et al. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention//Mol. Psychiatry.- 2018.- Vol. 23, №8.- P. 1764–1772. doi: 10.1038/mp.2017.249.
  49. Lieberman J.A., Small S.A., Girgis R.R. Early detection and preventive intervention in schizophrenia: from fantasy to reality//Am. J. Psychiatry.- 2019. – Vol. 176, №10.- P. 794–810. doi: 10.1176/appi.ajp.2019.19080865.
  50. Penttilä M., Jääskeläinen E., Hirvonen N., Isohanni M., Miettunen J.. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis//Br. J. Psychiatry.-2014.-Vol. 205, №2.-P. 88–94. doi: 10.1192/bjp.bp.113.127753.
  51. Dufort A., Zipursky R.B. Understanding and managing treatment adherence in schizophrenia// Clin. Schizophr. Relat. Psychoses.- 2019. https://doi.org/10.3371/CSRP. ADRZ.121218.
  52. Correll C.U., Rubio J.M., Kane J.M. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? //World Psychiatry.- 2018.-Vol.17, №2.- P.149–60. https:// doi. org/ 10. 1002/wps. 20516.
  53. Быков Ю.В., Беккер Р.А. Пролонгированные и сверхпролонгированные антипсихотики в поддерживающей терапии шизофрении: когда, как, кому? // Психиатрия и психофармакотерапия. – 2019. – № 21 (5). – С. 10–15.
  54. Петрова Н.Н. Роль современных пролонгированных антипсихотиков на ранних этапах шизофрении//Современная терапия психических расстройств.- 2019.- №4.-С. 11-18. DOI: 10.21265/PSYPH.2019.92.43.002
  55. Corigliano V., Comparelli A., Mancinelli I. et al. Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study// Schizophr Res Treatment.- 2018.- 4834135. doi: 10.1155/2018/4834135. PMID: 30245878; PMCID: PMC6136552.
  56. Emsley R., Chiliza B., Asmal L. et al. Long-acting injectable antipsychotics in early psychosis: A literature review // Early Interv Psychiatry. – 2013. – Vol. 7, №3. – P. 247–54. doi: 10.1111/eip.12027.
  57. Heres S., Lambert M., Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics // Eur Psych. – 2014. – Vol. 29, suppl. 2. – Pp. 1409–1413. doi: 10.1016/S0924-9338(14)70001-X.
  58. Петрова Н.Н. Факторы риска и превенция суицида при шизофрении: фокус на роли современных инъекционных антипсихотиков-пролонгов // Современная терапия психических расстройств. – 2021. – № 3. – С. 32–38. DOI:10.21265/PSYPH.2021.15.71.003
  59. Tiihonen J., Mittendorfer-Rutz E., Majak М. et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia // JAMA Psychiatry. – 2017. – Vol. 74, №7. – P. 686-693. doi: 10.1001/jamapsychiatry.2017.1322.
  60. Poloni N., Ielmini M., Caselli I. et al. Oral Antipsychotic Versus Long-Acting Injections Antipsychotic in Schizophrenia Spectrum Disorder: a Mirror Analysis in a Real-World Clinical Setting// Psychopharmacol Bull.- 2019.- Vol. 49, №2.- P.17-27. PMID: 31308579; PMCID: PMC6598776.
  61. Kane J.M., McEvoy J.P., Correll C.U., Llorca P.M. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia// CNS Drugs.- 2021.- Vol.35, №11.- P.1189-1205. doi: 10.1007/s40263-021-00861-6.
  62. Pietrini F., Albert U., Ballerini A. et al. The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia// Neuropsychiatr Dis Treat. – 2019.- Vol.15.- P.1045–60. https:// doi. org/ 10. 2147/ NDT. S1990 48.
  63. Hamann J., Heres S. Why and how family caregivers should participate in shared decision making in mental health// Psychiatr Serv.- 2019.- Vol.70, №5. – P. 418–21. https:// doi. org/ 10. 1176/ appi. ps. 20180 0362.
  64. Alguera-Lara V., Dowsey M.M., Ride J. et al. Shared decision making in mental health: the importance for current clinical practice// Australas Psychiatry.- 2017.- Vol. 25, №6.-P. 578–82. https:// doi.org/ 10. 1177/ 10398 56217 734711
  65. Correll C.U. Using Patient-Centered Assessment in Schizophrenia Care: Defining Recovery and Discussing Concerns and Preferences// J Clin Psychiatry.- 2020.- Vol.81, №3. MS19053BR2C. doi: 10.4088/JCP.MS19053BR2C. PMID: 32297720.
  66. Lauriello J. Patient-centered psychopharmacology and psychosocial interventions: treatment selection and shared decision making to enhance chances for recovery// J Clin Psychiatry. – 2020.- Vol. 81, №3:MS19053BR4C. https:// doi. org/ 10. 4088/ JCP. MS190 53BR4C.
  67. Pietrini F., Tatini L., Santarelli G. et al. Self- and caregiver-perceived disability, subjective well-being, quality of life and psychopathology improvement in long-acting antipsychotic treatments: a 2-year follow-up study//Int J Psychiatry Clin Pract.- 2021.- Vol. 25, №3. P. 307-315. doi: 10.1080/13651501.2021.1912358.
  68. Yoshimatsu K., Elser A., Thomas M. et al. Recovery-Oriented Outcomes Associated with Long-Acting Injectable Antipsychotics in an Urban Safety-Net Population//Community Ment Health J. -2019.-Vol. 55, №6. - P. 979-982. doi: 10.1007/s10597-019-00412-w.
  69. Петрова Н.Н., Иванов М.В., Костерин Д.Н. и др. Характеристика ремиссии у больных шизофренией на фоне лечения антипсихотическими препаратами пролонгированного действия//Психиатрия и психофармакотерапия.- 2015.- Т. 17, №5–6.-С. 20–25.
  70. Gorwood P., Bouju S., Deal C. et al. Predictive factors of functional remission in patients with early to mid-stage schizophrenia treated by long acting antipsychotics and the specific role of clinical remission//Psychiatry Res.- 2019.- Vol. 281. 112560. doi: 10.1016/j.psychres.2019.112560. Epub 2019 Sep 7. PMID: 31521843.

Downloads

Download data is not yet available.